Status:
COMPLETED
A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This type of study is called a radiolabeled study. For this study, LY2835219 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radio...
Eligibility Criteria
Inclusion
- Overtly healthy male or female participants as determined by medical history and physical examination
- Male participants will be sterile
- Female participants will be surgically sterile or postmenopausal
- Have a body mass index (BMI) of 18 to 29 kilograms per square meter (kg/m\^2)
- Have venous access sufficient to allow for blood sampling
Exclusion
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Gastrointestinal disorders causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01913314
Start Date
August 1 2013
End Date
October 1 2013
Last Update
January 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madison, Wisconsin, United States, 53704